Arvinas Stock Price, News & Analysis

Arvinas (Nasdaq: ARVN) will present preclinical data for ARV-806, a PROTAC KRAS G12D degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

The data will be shown as Poster B107 in Poster Session B on October 24, 2025 from 12:30–4:00 PM ET. The full abstract is available in the conference online program.

Arvinas (NASDAQ: ARVN) reported patient-reported outcomes from the Phase 3 VERITAC-2 trial showing vepdegestrant delayed deterioration in overall quality of life, pain, and multiple functioning domains versus fulvestrant in patients with ESR1-mutated ER+/HER2- advanced or metastatic breast cancer previously treated with endocrine-based therapy.

The trial enrolled 624 patients (270 with ESR1 mutations) across 213 sites in 25 countries; progression-free survival showed a statistically significant improvement and overall survival remains the key secondary endpoint.

Arvinas (Nasdaq: ARVN) will present new clinical data for vepdegestrant at the ESMO Congress, Oct 17–21, 2025 in Berlin.

Highlights include Phase 3 VERITAC-2 patient-reported outcomes comparing vepdegestrant (VEP) vs fulvestrant (FUL) in ESR1-mutated ER+/HER2− advanced/metastatic breast cancer, presented by Dr. Mario Campone on Oct 20, 2025 at 11:25 CEST (Presentation 489MO, mini oral). Also scheduled is TACTIVE-N, a Phase 2 neoadjuvant study of vepdegestrant vs anastrozole in postmenopausal localized ER+/HER2− breast cancer, presented by Dr. Peter A. Fasching on Oct 19, 2025 at 10:40 CEST (Presentation 293MO, mini oral).

Both abstracts are available in the ESMO online program.

Arvinas (Nasdaq: ARVN) announced late‑breaking Phase 1 data for ARV-102, an oral brain‑penetrant PROTAC LRRK2 degrader, presented at MDS 2025 on Oct 5, 2025.

The PR states ARV-102 was generally well tolerated (single doses up to 200 mg; multiple daily doses up to 80 mg) with no discontinuations or SAEs. Plasma and CSF exposure increased dose‑dependently, indicating brain penetration. The PR reports >90% PBMC LRRK2 reductions at ≥20 mg and median PBMC reductions of 86% (50 mg) and 97% (200 mg) in patients. In healthy volunteers, 14 days of 80 mg produced CSF proteomic decreases in lysosomal and microglial pathway markers linked to Parkinson’s disease.

Arvinas (NASDAQ:ARVN) announced two upcoming presentations featuring clinical data for ARV-102, their investigational PROTAC degrader targeting LRRK2 for Parkinson's disease, at the 2025 International Congress of Parkinson's Disease and Movement Disorders® in Honolulu.

The presentations include a first-in-human study examining safety, pharmacokinetics, and pharmacodynamics of ARV-102 in healthy participants, and a late-breaker presentation on pathway engagement in both healthy volunteers and Parkinson's disease patients. The sessions are scheduled for October 7-8, 2025.

Arvinas (NASDAQ:ARVN) announced significant strategic changes, including plans to out-license vepdegestrant commercialization rights with Pfizer to a third party. The drug is under FDA review for ER+/HER2- advanced breast cancer with a PDUFA date of June 5, 2026.

The company unveiled major cost optimization measures, including a 15% workforce reduction and operational streamlining, expecting to achieve over $100 million in annual savings compared to FY 2024. The Board authorized a $100 million stock repurchase program and reaffirmed cash runway through H2 2028.

Arvinas continues advancing three Phase 1 PROTAC degraders: ARV-102 for Parkinson's disease, ARV-393 for non-Hodgkin lymphoma, and ARV-806 for solid tumors.

Arvinas (NASDAQ:ARVN), a clinical-stage biotech company focused on targeted protein degradation, has announced its participation in two upcoming investor conferences. Management will engage in fireside chats at the Wells Fargo Healthcare Conference on September 4 and the Cantor Global Healthcare Conference on September 5.

Live audio webcasts of both presentations will be accessible through the company's website under the "Events and Presentations" section of the Investors and Media page.

Arvinas (NASDAQ:ARVN) and Pfizer announced the FDA's acceptance of the New Drug Application (NDA) for vepdegestrant, a novel treatment for ESR1-mutated, ER+/HER2- advanced breast cancer. The FDA has set a PDUFA date of June 5, 2026.

The application is supported by the pivotal Phase 3 VERITAC-2 trial, which demonstrated significant improvement in progression-free survival compared to fulvestrant. Notably, vepdegestrant is the first PROteolysis TArgeting Chimera (PROTAC) to show clinical benefit in breast cancer patients. The trial results were presented at ASCO 2025 and published in The New England Journal of Medicine.

Arvinas (NASDAQ:ARVN) reported Q2 2025 financial results and significant pipeline developments. The company submitted a New Drug Application for vepdegestrant for ESR1m, ER+/HER2- advanced breast cancer treatment, marking the first-ever PROTAC degrader submission. The Phase 3 VERITAC-2 trial showed a 2.9-month PFS improvement versus fulvestrant in specific patient populations.

Financial highlights include $861.2 million in cash and equivalents as of June 30, 2025, with funding runway into 2H 2028. Q2 revenue was $22.4 million, down from $76.5 million year-over-year, while R&D expenses decreased to $68.6 million from $93.7 million. The company also announced CEO John Houston's planned retirement.

Pipeline progress includes positive ARV-102 Phase 1 data in Parkinson's disease, promising ARV-393 preclinical results, and initiation of the ARV-806 Phase 1 trial for KRAS G12D mutations.